This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmacology is one of the most fundamental aspects of medication therapy. 1] How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs? Due to limited knowledge of pharmacology, the sales rep failed to properly communicate and was unable to address the physicians concerns.
In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex. Looking back at 2023 , AI for drug discovery saw both wins and losses.
There is a clear trend away from developing pharmacological therapies targeting opioid receptors” There is a clear trend away from developing pharmacological therapies targeting opioid receptors. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience. References Cruccu G, Truini A.
Companies are testing the use of digital platforms along with pharmacological treatments. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging. Securing reimbursement for digital therapeutics also continues to impede its uptake.
billion in 2022 to $4.1 percent between 2022 and 2032. percent between 2022 and 2032. GlobalData anticipated it will launch in the US and 5EU (France, Germany, Italy, Spain, and the UK) markets during the forecast period, Sulayman Patel, MSci, Pharma Analyst at GlobalData noted. “As percent from $3.2 billion in 2032.
It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.
Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.
On February 7, at a town hall organised to discuss clinical trial designs for gene therapies, FDA experts pushed pharma players to look for ways to establish clinical effectiveness despite the challenges in recruiting patients with rare diseases.
Research shows that the overall carbon emissions of the biotechnology sector globally totalled 193 million tCO2-e (tonnes of carbon dioxide equivalent) in 2022. References Carbon Impact of Biotech & Pharma Report: Collective Action Accelerating Progress to the UN Race to Zero. Pulmonary Pharmacology & Therapeutics.
The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.
Ahead of the world’s largest pharma event, CPHI Frankfurt – hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics outsourcing and contract manufacturing organisastions (CMOs) in 2023. percent in 2022.
Back in December 2022, President Biden signed a new law stating that novel medicines no longer needed to be tested on animals to receive U.S. They became integral to physiological and pharmacological research during the 19th century and started to be systematically used for drug development during the 20th century. Passini, E.,
Yet, despite the landmark FDA approval, digital pills have not exploded in pharma. The digital pill, now marketed by Otsuka Pharmaceuticals, is forecasted to make $27 million in sales in 2022, as per GlobalData. But the pharmacology to quantify adherence also depends on race, gender, weight, and other factors.
The highly anticipated Lipid Nanoparticle Immunogenicity & Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology , immunogenicity , bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.
billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 He received an MD from the Georg August University of Göttingen and completed a postdoctoral Master’s in Medical Sciences Clinical Pharmacology at the University of Glasgow. Available from: [link] Worldwide cancer statistics [Internet].
Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022. She continued: “In 2022, we don’t have any meaningful treatments to slow down dementia, but optimistically I’m a science and a neurologist; I’ve been seeing dementia patients for 25 years. We’re getting to 70 and beyond. It is about money.
Last year, IQVIA predicted that 2022 would be the crunch year for Alzheimer’s therapies: it is with a sense of déjà vu that the exact same prediction is contemplated for 2023. The European Medicine Agency-approved Biomarin’s Haemophilia A gene therapeutic, Roctavian, in 2022, and it is expected to be approved by the FDA in 2023.
Spearheaded by collaborations between non-profit groups and pharma players, new treatments are edging closer to late-stage trials in malaria and neglected tropical diseases such as sleeping sickness. Pharmaceutical Technology lists some of the top events in the tropical disease arena in 2022.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content